We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter International (BAX) Beats on Earnings And Sales in Q1
Read MoreHide Full Article
Headquartered in Deerfield, Illinois, Baxter International Inc. (BAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #3 (Hold) but that could change following its first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 58 cents per share beat the Zacks Consensus Estimate of 51 cents and increased by 22 cents from the year-ago quarter.
Revenues: Baxter posted sales of $2.47 billion, marginally beating the Zacks Consensus Estimate for revenues of $2.43 billion. At constant currency (cc), revenues increased almost 5% on a year-over-year basis.
Key Stats: Hospital products sales increased 7% at cc, while renal products inched up 1% from the year-ago quarter.
Major Factors: Hospital Products sales in the quarter were driven by solid sales in the U.S. for IV therapies, IV access sets, and select anesthesia and critical care products. Hospital Sales were also favorably impacted by solid demand for parenteral nutrition therapies and international bio-surgery products.
Renal products sales were driven by solid demand for continuous renal replacement therapies. Increased sales of peritoneal dialysis therapies driven by the continued adoption of the company’s newest Automated Peritoneal Dialysis (APD) cyclers also enhanced the renal products sales in the quarter.
Stock Price:Shares have risen roughly 13% over the past 3 months, while the Zacks categorized Medical Products sub industry has gained 7.6% over the same time frame.
Check back later for our full write up on this Baxter International report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Baxter International (BAX) Beats on Earnings And Sales in Q1
Headquartered in Deerfield, Illinois, Baxter International Inc. (BAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #3 (Hold) but that could change following its first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 58 cents per share beat the Zacks Consensus Estimate of 51 cents and increased by 22 cents from the year-ago quarter.
Revenues: Baxter posted sales of $2.47 billion, marginally beating the Zacks Consensus Estimate for revenues of $2.43 billion. At constant currency (cc), revenues increased almost 5% on a year-over-year basis.
Key Stats: Hospital products sales increased 7% at cc, while renal products inched up 1% from the year-ago quarter.
Baxter International Inc. Price and EPS Surprise
Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote
Major Factors: Hospital Products sales in the quarter were driven by solid sales in the U.S. for IV therapies, IV access sets, and select anesthesia and critical care products. Hospital Sales were also favorably impacted by solid demand for parenteral nutrition therapies and international bio-surgery products.
Renal products sales were driven by solid demand for continuous renal replacement therapies. Increased sales of peritoneal dialysis therapies driven by the continued adoption of the company’s newest Automated Peritoneal Dialysis (APD) cyclers also enhanced the renal products sales in the quarter.
Stock Price:Shares have risen roughly 13% over the past 3 months, while the Zacks categorized Medical Products sub industry has gained 7.6% over the same time frame.
Check back later for our full write up on this Baxter International report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>